Back to search results

Study of Artesunate for CMV Infection in Transplant Patients

This study is testing a drug called Artesunate, given along with standard treatments like Ganciclovir (GCV) or Valganciclovir (VGCV), for people who have had a solid organ transplant (like a kidney, lung, heart, or liver) and have a cytomegalovirus (CMV) infection. CMV is a common virus that can cause problems in transplant patients. We want to see if adding Artesunate helps reduce the amount of CMV in your blood (CMV DNAemia) more effectively than standard treatment alone. You could be eligible if you are at least 18 years old, have had a solid organ transplant, have a documented CMV infection, and need IV GCV or oral VGCV. The study plans to enroll about 90 participants, but its current status is unclear.

Study design
This is a randomized, open-label study comparing different doses of Artesunate plus standard treatment to standard treatment alone. About 90 participants are planned for this study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goal is to measure the reduction of CMV in your blood at 28 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06853184

Study Evaluating the Efficacy and Safety of Artesunate

Recruiting
PHASE2Ages 18+InterventionalTreatment
Amivas Inc.
~90 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:ArtesunateGanciclovir (GCV)

At a glance

Recruiting sites
2 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reduction of cytomegalovirus (CMV) DNAemia
Measured over 28 days

Conditions

CMV Infection

Explore related trials

Cytomegaloviral Infection

NCT06853184

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australiano site contact published

    Terminated

  • Westmead Hospital

    Westmead, Australiano site contact published

    Terminated

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Bryan Smith
[email protected]
301-807-8548
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be at least 18 years of age
Recipient of a solid organ transplant (kidney, lung, heart, or liver)
Have a documented CMV infection
Have CMV DNAemia
Require IV GCV or oral VGCV
Be washed out from any anti-CMV antiviral drugs
Have all the following results as part of screening laboratory assessments
Have life expectancy of ≥ 12 weeks
Be willing and have an understanding and ability to fully comply with the study
If female use birth control

Exclusion

Have taken IV GCV or oral VGC daily for \>8 days
Have refractory CMV infection or disease
Have CMV antiviral drug resistance
Have a known hypersensitivity to artesunate, GCV, or VGCV
Pregnant (or expecting to conceive) or nursing
Have severe liver disease
Require ongoing treatment with or an anticipated need for treatment with drugs with known interactions with artesunate or GCV
Taking any another investigational drug with anti-CMV activity

What this trial measures

  • Reduction of cytomegalovirus (CMV) DNAemia28 days

    Determine if Artesunate for Injection (intravenous \[IV\] artesunate) when administered in combination with IV Ganciclovir (GCV) and/or oral valganciclovir (VGCV) and standard of care (SOC) treatment impacts change of cytomegalovirus (CMV) DNAemia compared with those who only received GCV or VGCV and SOC treatment